BAYPAN study: A double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer

Annals of Oncology

Volumn 23, Issue 11, 2012, Pages 2799-2805

  Goncalves A ^a,b,c,d   Gilabert, M ^a   Francois E ^e   Dahan, L ^c,d,f   Perrier, H ^g   Lamy, R ^h   Re, D ⁱ   Largillier, R ^j   Gasmi, M ^k   Tchiknavorian, X ^l   Esterni, B ^a,d   Genre, D ^a,d   Moureau Zabotto, L ^a   Giovannini, M ^a   Seitz, J F ^c,d,f   Delpero, J R ^a,b,c,d   Turrini, O ^a,b,c   Viens, P ^a,b,c,d   Raoul, J L ^a,b  

^a INSTITUT PAOLI CALMETTES   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d Clinical Investigation Center 9502   (France)

^e CENTRE ANTOINE LACASSAGNE   (France)

^f TIMONE HOSPITAL   (France)

^g HÔPITAL SAINT JOSEPH   (France)

^h Centre Hospitalier de Lorient   (France)

ⁱ CHG Antibes Juan les Pins   (France)

^j Centre Azuréen Cancérologie   (France)

^k HÔPITAL NORD   (France)

^l Centre Hospitalier Intercommunal Toulon La Seyne sur Mer   (France)

more..

Author keywords

Advanced pancreatic cancer; Gemcitabine; Phase III randomized trial; Sorafenib

Indexed keywords

EID: 84868107516     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds135     Document Type: Article

References (34)

1. Hidalgo M. Pancreatic cancer. N Engl J Med 2010; 362: 1605-1617.
2. Burris HA, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first- line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413.
3. Heinemann V, Boeck S, Hinke A et al. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008; 8: 82.
4. Sultana A, Smith CT, Cunningham D et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 2007; 25: 2607-2615.
5. Herrmann R, Bodoky G, Ruhstaller T et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007; 25: 2212-2217.
6. Stathopoulos GP, Syrigos K, Aravantinos G et al. A multicentre phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as firstline treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer 2006; 95: 587-592.
7. Heinemann V, Quietzsch D, Gieseler F et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006; 24: 3946-3952.
8. Louvet C, Labianca R, Hammel P et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23: 3509-3516.
9. Di Costanzo F, Carlini P, Doni L et al. Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC). Br J Cancer 2005; 93: 185-189.
10. Rocha Lima CM, Green MR, Rotche R et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004; 22: 3776-3883.
11. Cunningham D, Chau I, Stocken DD et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009; 27: 5513-5518.
12. Philip PA, Benedetti J, Corless CL et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-Directed Intergroup Trial S0205. J Clin Oncol 2010; 28: 3605-3610.
13. Kindler HL, Niedzwiecki D, Hollis D et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010; 28: 3617-3622.
14. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966.
15. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109.
16. Ulivi P, Arienti C, Amadori D et al. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines. J Cell Physiol 2009; 220: 214-221.
17. Vincent P, Zhang X, Chen C et al. Chemotherapy with the raf kinase inhibitor BAY 43-9006 in combination with irinotecan, vinorelbine, or gemcitabine is well tolerated and efficacious in preclinical xenograft models. Proc Am Soc Clin Oncol 2002; 21: 2002.
18. Siu LL, Awada A, Takimoto CH et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res 2006; 12: 144-151.
19. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
20. El-Khoueiry AB, Ramanathan RK, Yang DY et al. A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer. Invest New Drugs, 2011
21. Berardi R, Sobrero A, Labianca R et al. Sorafenib does not improve the results of chemotherapy in advanced pancreatic cancer: a GISCAD randomised phase II trial. Ann Oncol 2010; 21: viii225-viii249.
22. Philip PA, Mooney M, Jaffe D et al. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol 2009; 27: 5660-5669.
23. Van Cutsem E, Vervenne WL, Bennouna J et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009; 27: 2231-2237.
24. Kindler HL, Ioka T, Richel DJ et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a doubleblind randomised phase 3 study. Lancet Oncol 2011; 12: 256-262.
25. Ott PA, Hamilton A, Min C et al. A phase II trial of sorafenib in metastatic melanoma with tissue correlates. PLoS One 2010; 5: e15588.
26. Ott PA, Hamilton A, Min C et al. A phase II trial of sorafenib in metastatic melanoma with tissue correlates. PLoS One 5: e15588.
27. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516.
28. Hatzivassiliou G, Song K, Yen I et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010; 464: 431-435.
29. Poulikakos PI, Zhang C, Bollag G et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464: 427-430.
30. Su F, Viros A, Milagre C et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF Inhibitors. N Engl J Med 2012; 366: 207-215.
31. Weeraratna AT. RAF around the Edges "The Paradox of BRAF Inhibitors". N Engl J Med 2012; 366: 271-273.
32. Yamamoto S, Tomita Y, Hoshida Y et al. Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res 2004; 10: 2846-2850.
33. Edling CE, Selvaggi F, Buus R et al. Key role of phosphoinositide 3-kinase class IB in pancreatic cancer. Clin Cancer Res 16: 4928-4937.
34. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825.